Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
International expertise returns to Belgium
AppointmentsVIB and Flemish Minister of Economy and Innovation, Hilde Crevits, announce the appointment of Dr Christine Durinx as VIB’s co-managing director, alongside Dr Jérôme Van Biervliet. Dr Jo Bury, co-founder and co-managing director since VIB’s inception 25 years ago, is passing the torch to Durinx who is the former Executive Director of the SIB Swiss Institute of Bioinformatics.
EMA delays Valneva vaccine approval
Latest NewsThe approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.
Mimetas BV participating in €325m cancer funding
Latest NewsOrgan-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharma’s imlifidase advances to Phase III testing
Latest NewsThe US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
Latest NewsGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
Latest NewsA 3D tumour model developed by scientists enables drug screening in metastases
Vetter wins at the 2022 CMO Leadership Awards
BackgroundVetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
Affimed prices public offering to finance NK cell trials
Latest NewsFollowing phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Latest NewsSwiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Lead optimisation – the sequence is the key
BackgroundThe efficacy of therapeutic antibodies is defined by their primary amino acid sequence. After discovery, antibody candidates often profit from protein engineering and sequence optimisation. Different technologies can improve the functional properties of antibodies as well as their biochemical and biophysical characteristics influencing manufacturing, process development, formulation, and other parameters of the final drug target product profile.